Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I see Mugsy and Magicrotch are silent today

<< Previous

Bullboard Posts

Next >>

Comment by TechMooseon Oct 04, 2021 6:26pm

156 Views

Post# 33964857

RE:RE:I see Mugsy and Magicrotch are silent today

Well done Mugs...Way to silence Mr. Yukon...At least for a few minutes.

Appreciate your posts....Always sticking to facts. Well researched and presented… Never making it personal. Not getting dragged into the mud - unfortunately that's where these short sellers and attention seekers like to wrestle. They have little to add to this board. I've added to my position. GLTAL!

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project